The Safety and Effectiveness of Cidofovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

Inclusion Criteria Concurrent Medication: Allowed: * Antiretroviral agents. * Oral trimethoprim/sulfamethoxazole. * Aerosolized pentamidine. * Dapsone. * Fluconazole. * Rifabutin. * Filgrastim (G-CSF). * p24 vaccine. Patients must have: * Diagnosis of AIDS by CDC criteria. * Diagnosis of peripheral (not immediately sight-threatening) CMV retinitis. * Visual acuity in the affected eye of \>= three lines on the ETDRS (Early Treatment Diabetic Retinopathy Study) chart at 1 m distance. * Life expectancy of at least 3 months. * Consent of parent or guardian in patients less than 18 years of age. Prior Medication: Allowed: * Acyclovir. * Prior ganciclovir, foscarnet, or CMV hyperimmune immunoglobulin if given solely as prophylaxis. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Media opacity that precludes visualization of the fundus of both eyes. * Retinal detachment. * Clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia. * Active medical problems considered sufficient to hinder study compliance. * Known clinically significant allergy to probenecid. Concurrent Medication: Excluded: * Acyclovir (may be reinstituted following development of herpetic lesions). * Ganciclovir. * Foscarnet. * Amphotericin B. * Diuretics. * Aminoglycoside antibiotics. * CMV hyperimmune immunoglobulin. * Intravenous pentamidine. * Other nephrotoxic agents. * Other investigational drugs with potential nephrotoxicity. Prior Medication: Excluded: * Prior ganciclovir, foscarnet, or CMV hyperimmune immunoglobulin as therapy for CMV disease (although permitted if previously received solely as prophylaxis). Excluded within 1 week prior to study entry: * Amphotericin B. * Vidarabine. * Other nephrotoxic agents. * Aminoglycoside antibiotics. * Intravenous pentamidine. Drug or alcohol abuse.